ArticleInnere Medizin (Heidelberg, Germany)2026
[Treatment of type 2 diabetes mellitus].
Article in Innere Medizin (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Modern diabetology is undergoing a paradigm shift from glucose-centric management toward risk-adapted precision medicine. Differentiated phenotyping into clusters allows for the early identification of organ-specific risks. Pharmacotherapy now prioritizes cardiorenal protection using sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide‑1 (GLP-1) receptor agonists, and nonsteroidal mineralocorticoid receptor antagonists (nsMRAs; finerenone), which reduce vascular events beyond glycated hemoglobin (HbA1c) reduction alone. Technological innovations, such as continuous glucose monitoring (CGM), complement traditional markers with dynamic metrics such as time in range. A new, realistic therapeutic goal is metabolic remission, facilitated by potent incretin mimetics and early intervention during the prediabetes stage. The ultimate objective is the sustainable restoration of normoglycemia and the prevention of end-organ damage through a multifactorial, individualized approach.
Indexed as
Identifiers
42895644What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.